Understanding and treating immune-related side effects from cancer therapies
Official title: Mechanism-rooted therapeutic strategies for immune-related toxicities induced by checkpoint inhibitors
Funded at University of Tx Md Anderson Can Ctr · NIH-10861932 · Data updated 2026-11-12
This study is looking into the side effects that some cancer treatments can cause, like joint pain or lung issues, to better understand why they happen and find ways to help manage them for patients receiving these treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $352,047 |
| NIH project number | 5R01CA284684-02 |
| Project ID | NIH-10861932 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include cancer patients undergoing treatment with immune checkpoint inhibitors who are experiencing or at risk of developing immune-related adverse events.
✕Less likely to help
Patients who are not receiving immune checkpoint inhibitors or those without any immune-related adverse events may not benefit from this research.
What this research studies
This research investigates the immune-related adverse events (irAEs) that can occur in patients receiving immune checkpoint inhibitors (ICIs) for cancer treatment. It aims to identify the mechanisms behind these complications, such as arthritis, colitis, and pneumonitis, which can threaten patient health. By studying both human samples and mouse models, the research seeks to characterize the immune responses associated with these adverse events and develop targeted therapeutic strategies to manage them effectively.
Why it matters
Potential benefit: If successful, this research could lead to improved management of immune-related side effects, enhancing the safety and efficacy of cancer treatments.
How similar studies have gone: Previous research has shown promising results in understanding immune-related adverse events, but this study aims to explore novel mechanisms and therapeutic strategies that have not been extensively tested.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Nurieva, Roza Insafetdinovna — University of Tx Md Anderson Can Ctr
- Study coordinator: Nurieva, Roza Insafetdinovna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.